CoronaVac, an inactivated SARS-CoV-2 vaccine, has been approved for emergency use in
several countries. However, its immunogenicity in immunocompromised individuals has not …

Objective To determine the immunogenicity of the third dose of CoronaVac vaccine in a
large population of patients with autoimmune rheumatic diseases (ARD) and the factors …

COVID-19 vaccines are of great importance in reducing SARS-CoV-2 infection and severe
cases. Patients with autoimmune inflammatory rheumatic diseases (AIIRDs) have been …

CoronaVac, also known as the Sinovac inactivated SARS-CoV-2 vaccine, has been widely
implemented in combating the COVID-19 pandemic. We summarized the results of clinical …

ABSTRACT BACKGROUND The top priority for the control of COVID-19 pandemic currently
is the development of a vaccine. A phase 2 trial conducted to further evaluate the …

Background CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown
to be well tolerated with a good safety profile in individuals aged 18 years and older in …

Background The ongoing COVID-19 pandemic has had a significant impact worldwide, with
an incommensurable social and economic burden. The rapid development of safe and …

Background Large-scale vaccination against COVID-19 is being implemented in many
countries with CoronaVac, an inactivated vaccine. We aimed to assess the immune …

Introduction In light of the SARS-CoV-2 pandemic, protecting vulnerable groups has become
a high priority. Persons at risk of severe disease, for example, those receiving …

Background With the unprecedented morbidity and mortality associated with the COVID-19
pandemic, a vaccine against COVID-19 is urgently needed. We investigated CoronaVac …